Literature DB >> 20383543

Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds.

John T Pinto1, Jeong-In Lee, Raghu Sinha, Melanie E MacEwan, Arthur J L Cooper.   

Abstract

Previous studies on the chemopreventive mechanisms of dietary selenium have focused on its incorporation into antioxidative selenoproteins, such as glutathione peroxidase and thioredoxin reductase. Several studies, however, have revealed that dietary selenium in the form of L-selenomethionine and the 21st amino acid, selenocysteine, also have intrinsic anti-cancer properties. Biochemical mechanisms previously investigated to contribute to their anticancer effects involve β- and γ-lyase reactions. Some pyridoxal 5'-phosphate (PLP)-containing enzymes can catalyze a β-lyase reaction with Se-methyl-L-selenocysteine (MSC) generating pyruvate and ammonia. Other PLP-enzymes can catalyze a γ-lyase reaction with L-selenomethionine (SM) generating α-ketobutyrate and ammonia. In both cases, a purported third product is methylselenol (CH(3)SeH). Although not directly quantifiable, as a result of its extreme hydrophobicity and high vapor pressure, CH(3)SeH has been indirectly observed to act through the alteration of protein-sulfhydryl moieties on redox-responsive signal and transcription factors, thereby maintaining a non-proliferative intracellular environment. We have considered the possibility that α-keto acid analogues of MSC (i.e., methylselenopyruvate; MSP) and SM (i.e., α-keto-γ-methylselenobutyrate; KMSB), generated via a transamination and/or L-amino acid oxidase reaction may also be chemoprotective. Indeed, these compounds were shown to increase the level of histone-H3 acetylation in human prostate and colon cancer cells. MSP and KMSB structurally resemble butyrate, an inhibitor of several histone deacetylases. Thus, the seleno α-keto acid metabolites of MSC and SM, along with CH(3)SeH derived from β- and γ-lyase reactions, may be potential direct-acting metabolites of organoselenium that lead to de-repression of silenced tumor suppressor proteins and/or regulation of genes and signaling molecules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383543      PMCID: PMC2965792          DOI: 10.1007/s00726-010-0578-3

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  90 in total

1.  Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells.

Authors:  Cheng Jiang; Zaisen Wang; Howard Ganther; Junxuan Lü
Journal:  Mol Cancer Ther       Date:  2002-10       Impact factor: 6.261

2.  A sensitive fluorometric assay for amino acid oxidases.

Authors:  L A Lichtenberg; D Wellner
Journal:  Anal Biochem       Date:  1968-11       Impact factor: 3.365

3.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Authors:  V M Richon; T W Sandhoff; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  Catalytic selenols couple the redox cycles of metallothionein and glutathione.

Authors:  Y Chen; W Maret
Journal:  Eur J Biochem       Date:  2001-06

5.  Aminotransferase, L-amino acid oxidase and beta-lyase reactions involving L-cysteine S-conjugates found in allium extracts. Relevance to biological activity?

Authors:  Arthur J L Cooper; John T Pinto
Journal:  Biochem Pharmacol       Date:  2005-01-15       Impact factor: 5.858

6.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

Review 7.  Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds.

Authors:  R Sinha; K El-Bayoumy
Journal:  Curr Cancer Drug Targets       Date:  2004-02       Impact factor: 3.428

8.  Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite.

Authors:  Guang-xun Li; Hyo-Jeong Lee; Zhe Wang; Hongbo Hu; Joshua D Liao; Jennifer C Watts; Gerald F Combs; Junxuan Lü
Journal:  Carcinogenesis       Date:  2008-02-28       Impact factor: 4.944

Review 9.  Targeted histone deacetylase inhibition for cancer therapy.

Authors:  D M Vigushin; R C Coombes
Journal:  Curr Cancer Drug Targets       Date:  2004-03       Impact factor: 3.428

Review 10.  Status of selenium in prostate cancer prevention.

Authors:  G F Combs
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  26 in total

1.  Remarkable inhibition of mTOR signaling by the combination of rapamycin and 1,4-phenylenebis(methylene)selenocyanate in human prostate cancer cells.

Authors:  Nicole D Facompre; Indu Sinha; Karam El-Bayoumy; John T Pinto; Raghu Sinha
Journal:  Int J Cancer       Date:  2012-03-20       Impact factor: 7.396

2.  Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate.

Authors:  Arthur J L Cooper; Boris F Krasnikov; John T Pinto; Hank F Kung; Jianyong Li; Karl Ploessl
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2012-05-19       Impact factor: 2.231

Review 3.  Dietary factors and epigenetic regulation for prostate cancer prevention.

Authors:  Emily Ho; Laura M Beaver; David E Williams; Roderick H Dashwood
Journal:  Adv Nutr       Date:  2011-11-03       Impact factor: 8.701

4.  Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate β-lyase activity and can transaminate L-selenomethionine.

Authors:  John T Pinto; Boris F Krasnikov; Steven Alcutt; Melanie E Jones; Thambi Dorai; Maria T Villar; Antonio Artigues; Jianyong Li; Arthur J L Cooper
Journal:  J Biol Chem       Date:  2014-09-17       Impact factor: 5.157

Review 5.  Therapeutic perspectives of epigenetically active nutrients.

Authors:  M Remely; L Lovrecic; A L de la Garza; L Migliore; B Peterlin; F I Milagro; A J Martinez; A G Haslberger
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  Neuroprotective Benefits of Aerobic Exercise and Organoselenium Dietary Supplementation in Hippocampus of Old Rats.

Authors:  José L Cechella; Marlon R Leite; Simone Pinton; Gilson Zeni; Cristina W Nogueira
Journal:  Mol Neurobiol       Date:  2017-05-25       Impact factor: 5.590

Review 7.  Cysteine S-conjugate β-lyases: important roles in the metabolism of naturally occurring sulfur and selenium-containing compounds, xenobiotics and anticancer agents.

Authors:  Arthur J L Cooper; Boris F Krasnikov; Zoya V Niatsetskaya; John T Pinto; Patrick S Callery; Maria T Villar; Antonio Artigues; Sam A Bruschi
Journal:  Amino Acids       Date:  2010-03-22       Impact factor: 3.520

Review 8.  Metabolism as a key to histone deacetylase inhibition.

Authors:  Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-04-05       Impact factor: 8.250

9.  Bioaccessible selenium sourced from Se-rich mustard cake facilitates protection from TBHP induced cytotoxicity in melanoma cells.

Authors:  Sumit K Jaiswal; Ranjana Prakash; K Sandeep Prabhu; N Tejo Prakash
Journal:  Food Funct       Date:  2018-04-25       Impact factor: 5.396

10.  Methylselenol formed by spontaneous methylation of selenide is a superior selenium substrate to the thioredoxin and glutaredoxin systems.

Authors:  Aristi P Fernandes; Marita Wallenberg; Valentina Gandin; Sougat Misra; Francesco Tisato; Cristina Marzano; Maria Pia Rigobello; Sushil Kumar; Mikael Björnstedt
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.